KRAS and cancer: HCT116 cells with KRAS G13D and PIK3CA H1047R mutations (cancer.sanger.ac.uk) were cultured in the presence of both AZD6244 (MEK inhibitor) and BKM120 (PI3K inhibitor) at IC50 concentrations of each agent, AZD6244 alone (2 treatments of 1⁄2 IC50 concentrations), BKM120 alone (2 treatments of 1⁄2 IC50 concentrations), or vehicle (2 treatments of 0.25% DMSO).